임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-13 23:30
논문번호 90
논문제목(영문) Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Li YJ
교신저자명 Rha SW
공동저자명 Li YJ, Rha SW, Chen KY, Poddar KL, Jin Z, Minami Y, Wang L, Dang Q, Li GP, Ramasamy S, Park JY, Choi CU, Kim JW, Kim EJ, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Park JS, Kim YJ, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae
게제년월일 2009-12-14
ISSN 0002-8703
Impact Factor 4.463
학술지명 American heart journal
서지사항 0집 / 159권 / 4호,   페이지(684 - 690)
요약초록문
(Abstract) 입력		 BACKGROUND:
Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) remains unclear.
METHODS:
A total of 3,372 STEMI patients who underwent primary PCI with DESs received either LMWH (n = 1,531 patients, subcutaneous enoxaparin 1 mg/kg, bid for 3-5 days plus reduced dose of UFH [50 U/kg] during PCI) or UFH alone (n = 1,841 patients, intravenous bolus injection of 5,000 U, followed by 24,000 U/d infusion for at least 48 hours). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared.
RESULTS:
The incidences of major and minor bleeding events were similar between the 2 groups. Multivariable Cox regression analysis showed that LMWH group had lower incidences of cardiac death (adjusted odds ratio [OR] 0.55, 95% CI 0.39-0.77, P < .001), total death (adjusted OR 0.50, 95% CI 0.37-0.68, P < .001), and total major adverse cardiac events (adjusted OR 0.77, 95% CI 0.62-0.95, P = .017) at 8 months as compared with UFH group. Similar results were obtained across different subgroups including different DESs, age, and sex.
CONCLUSIONS:
The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion.
파일  C90.+Am+Heart+J.+2010;159(4)684-690..pdf (388.1K) DATE : 2021-05-25 13:09:26